The effect of botulinum toxin on decrease of sialorrhea in patients with neurologic disorder

The evaluation of botulinum toxin efficacy on drooling of the patients referring to neurology department of Ahvaz Golestan hospital

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013110515289N1

Enrollment

Registered

2013-12-19

Start date

2013-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sialorrhea. Disturbances of salivary secretion

Interventions

Dysport is an injection containing abobotulinumtoxinA (Botulinum toxin type A). AbobotulinumtoxinA is made from the bacteria that cause botulism. Dysport blocks the release of acetylcholine and a numb

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

10 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: between 10-85 years old patient with any neurologic disorder that suffers from sialorrhea Exclusion criteria: 1- Any neuromuscular junction disease 2-Pregnancy or lactation period 3-History of any salivary gland tumor or inflammatory disease 4-Infection of injection site

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of sialorrhea. Timepoint: Before injection-6 and 12 weeks after injection. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba khademiyan ghadikolaee, MD

Ahvaz Jundishapur University of Medical Sciences

khademiyan.m@ajums.ac.ir+98 61 1374 1093

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026